
April 22 (Reuters) - Compass Pathways PLC CMPS.O:
COMPASS PATHWAYS ANNOUNCES DOSING COMPLETE FOR ALL PARTICIPANTS IN PART A OF PHASE 3 COMP005 TRIAL OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION
COMPASS PATHWAYS PLC - TOP-LINE 6-WEEK PRIMARY ENDPOINT RESULTS EXPECTED IN LATE JUNE